SYK Inhibitor Entospletinib in Combination with Obinutuzumab Demonstrates Efficacy in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)

B-cell receptor (BCR) signaling kinases are important targets in therapy of CLL. Resistance of lymphoid niche-resident CLL cells to BCR-signaling inhibition is fostered by the tumor microenvironment. We found that stromal B-cell activation factor (BAFF)-mediated activation of spleen tyrosine kinase...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Blood 2019-11, Vol.134 (Supplement_1), p.4295-4295
Hauptverfasser:	Kittai, Adam S., Best, Scott R, Thurlow, Bria, Gokcora, Basak, Stadnik, Andrzej, MacKinnon, Renee, Rowland, Taylor Hashiguchi, Persky, Daniel O., Park, Byung, Spurgeon, Stephen E, Danilov, Alexey
Format:	Artikel
Sprache:	eng
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!